Nakao A, et al. - Given that, carboplatin + nab-paclitaxel (PTX) therapy vs carboplatin + PTX has been shown to be superior in terms of response rate (RR) and non-inferior in terms of progression free survival and overall survival in untreated patients with stage IIIB/IV non-small cell lung cancer (NSCLC) in a global multicenter study, researchers investigated the effectiveness and safety of maintenance therapy with nab-PTX after carboplatin + nab-PTX combination therapy. They observed a limited transition rate from induction to maintenance phase and presumed this to be responsible for nab-PTX showing no statistical significance as a maintenance therapy, however, it was suggested that nab-PTX has utility following the induction therapy with nab-PTX in patients with advanced NSCLC.